FDA Proposes Guidance to Expedite Cancer Drug Safety Testing

The U.S. Food and Drug Administration has released a draft guidance document. This proposal aims to reduce the need for animal testing in nonclinical safety assessments for certain cancer medications. The initiative seeks to accelerate the regulatory process, potentially lowering development costs and speeding up access to new treatments.